Cramer’s lightning round: These are the two pot stocks I’m recommending

Investing News

Tilray Inc.: “Tilray’s OK. Big short squeeze. We’ve got two that we like: our favorite is Canopy [Growth]. That’s because they’ve got the $4 bil[lion] from Constellation. And our second one is going to be Cronos [Group]. And we’re going to stick with our two. Those are the ones that brought us here.”

Fitbit Inc.: “I would’ve liked Fitbit at one time like I would’ve liked Fossil. I know, obviously, Fitbit is better in terms of health, but the Apple Watch is king. And while Fitbit can sneak back, you know: own Apple, don’t trade it.”

Moderna Inc.: “I pulled up with these guys when I was at the J.P. Morgan Healthcare Conference and I was quite impressed. I think it is a winner. Now, a little speculative, but you’ve got a good call.”

Exelixis Inc.: “We like Exelixis. We think that it’s got a lot of good stuff, but we realize that it is speculative. We profiled it several times and we’re on board.”

Maxar Technologies Inc.: “No, no, no. Way too speculative. I don’t know why it will bounce. I’m going to have to say don’t buy.”

International Paper Co.: “I wish that they really were a play on paper straws. I made the same mistake with Westrock. They’re really a play on worldwide growth and there isn’t enough worldwide growth right now, so we’re going to stay away from IP.”

Disclosure: Cramer’s charitable trust owns shares of Apple and J.P. Morgan.

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagram

Questions, comments, suggestions for the “Mad Money” website?

Products You May Like

Articles You May Like

Here are the cities where retirees rely the most on Social Security income
Why All the Jobs Cuts Are Actually Good for Tesla Stock
The Fed could move markets this week when it tells us what it was thinking at the January meeting
3 Dividend Stocks to Power Through Earnings Season
Mattel has worst day in nearly 20 years after undercutting analysts’ 2019 estimates

Leave a Reply

Your email address will not be published. Required fields are marked *